Thomas White International Ltd. cut its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 9.6% during the second quarter, HoldingsChannel.com reports. The fund owned 12,531 shares of the biotechnology company’s stock after selling 1,337 shares during the period. Thomas White International Ltd.’s holdings in Grifols were worth $217,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of GRFS. Atria Investments LLC increased its stake in Grifols by 17.1% during the 1st quarter. Atria Investments LLC now owns 84,905 shares of the biotechnology company’s stock worth $1,468,000 after buying an additional 12,387 shares during the period. Credit Suisse AG raised its position in Grifols by 23.7% in the 1st quarter. Credit Suisse AG now owns 135,406 shares of the biotechnology company’s stock valued at $2,341,000 after purchasing an additional 25,952 shares during the last quarter. Brandes Investment Partners LP raised its position in Grifols by 224.7% in the 2nd quarter. Brandes Investment Partners LP now owns 3,213,036 shares of the biotechnology company’s stock valued at $55,747,000 after purchasing an additional 2,223,608 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Grifols by 18.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 7,494 shares of the biotechnology company’s stock worth $129,000 after buying an additional 1,177 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Grifols by 59.2% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 15,106 shares of the biotechnology company’s stock worth $261,000 after buying an additional 5,619 shares during the last quarter. 14.08% of the stock is currently owned by institutional investors.
NASDAQ GRFS opened at $15.29 on Friday. The company has a current ratio of 1.69, a quick ratio of 0.58 and a debt-to-equity ratio of 0.97. Grifols, S.A. has a 1 year low of $14.01 and a 1 year high of $20.49. The stock’s 50-day moving average price is $14.81 and its two-hundred day moving average price is $16.54. The company has a market cap of $10.37 billion, a PE ratio of 13.41, a PEG ratio of 1.00 and a beta of 0.56.
GRFS has been the subject of a number of research analyst reports. Zacks Investment Research downgraded shares of Grifols from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 6th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Grifols in a research report on Wednesday, August 4th. Credit Suisse Group restated an “outperform” rating on shares of Grifols in a report on Wednesday, August 4th. Finally, Barclays reiterated an “overweight” rating on shares of Grifols in a research note on Monday, June 28th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $20.00.
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy.
Featured Article: Why are analyst ratings important in trading stocks?
Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFS).
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.